Safety and tolerability of MK0731 administered as a 24-hour CIV Infusion. Dose limiting toxicities. Maximum tolerated dose and recommended Phase II dose of L-001154704 administered as a 24 hour CIV infusion.
Predose predictive biomarkers of response to MK0731
18 Years and older (Adult, Senior)
February 28, 2005
January 30, 2015
† Study has passed its completion date and status has not been verified in more than two years.